Abbott Laboratories plans to sell more than $10 billion of fixed-income securities this week, according to Fox News, as it prepares to spin off its pharmaceutical operations into a new company, AbbVie.
Abbott announced Friday that it was offering to buy back up to $7.7 billion in nine outstanding debt issues that mature between 2014 and 2040. It said that its subsidiary, AbbVie, will sell debt and use the proceeds to pay Abbott a dividend.
Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.
Your access to unlimited Treasury & Risk content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
- Exclusive discounts on ALM and Treasury & Risk events.
- Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.
*May exclude premium content
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
